Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of BAT2506 vs Simponi in Healthy Chinese Males
NCT04152759Phase 1Completed
- Sponsor
- Bio-Thera Solutions, Ltd.
- Start
- Sep 2019
- Primary completion
- Dec 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BAT2506 in psoriatic arthritis (PsA) (2 arms), sponsored by Bio-Thera Solutions, Ltd. Primary endpoints: Area Under the Serum Concentration-Time Curve From Time Zero to Time t and Maximum Serum Concentration. Started Sep 2019; status: completed.
02
Drugs
BAT2506
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT04152759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04152759.